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Abstract
Background: Several strategies and devices have been designed to protect health care providers from
acquiring transmissible respiratory diseases while providing care. In modulating the physical characteristics
of the respiratory secretions to minimize the aerosolization that facilitates transmission of airborne
diseases, a fundamental premise is that the prototype drugs have no adverse effect on the first line of
respiratory defense, clearance of mucus by ciliary action.
Methods: To assess and demonstrate the primary mechanism of our mucomodulators (XLs), we have
built our evidence moving from basic laboratory studies to an ex-vivo model and then to an in-vivo large
animal model. We exposed anesthetized dogs without hypersecretion to different dose concentrations of
aerosolized XL "B", XL "D" and XL "S". We assessed: cardio-respiratory pattern, tracheal mucus clearance,
airway patency, and mucus viscoelastic changes.
Results: Exposure of frog palate mucus to XLs did not affect the clearance of mucus by ciliary action. Dogs
maintained normal cardio-respiratory pattern with XL administration. Tracheal mucociliary clearance in
anesthetized dogs indicated a sustained 40% mean increase. Tracheal mucus showed increased filance, and
there was no mucus retention in the airways.
Conclusion: The ex-vivo frog palate and the in-vivo mammalian models used in this study, appear to be
appropriate and complement each other to better assess the effects that our mucomodulators exert on
the mucociliary clearance defence mechanism. The physiological function of the mucociliary apparatus was
not negatively affected in any of the two epithelial models. Airway mucus crosslinked by mucomodulators
is better cleared from an intact airway and normally functioning respiratory system, either due to
enhanced interaction with cilia or airflow-dependent mechanisms. Data obtained in this study allow us to
assure that we have complied with the fundamental requirement criteria established in the initial phase of
developing the concept of mucomodulation: Can we modulate the physical characteristics of the
respiratory secretions to reduce aerosolization without affecting normal mucociliary clearance function,
or even better improving it?
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Background
The respiratory system performs one of the most vital
functions of the body: the respiratory process, that con-
sists of an appropriate gas exchange occurring in the lungs
between blood and air. It provides oxygen to the organism
and removes carbon dioxide. Air has to travel through a
series of passages, and interact with several types of tis-
sues, until it reaches the alveolus where the gas exchange
takes place. Air is in contact with many bacteria, pollut-
ants and particles in the environment before reaching the
alveolus. Many of these components are inert partici-
pants, but others are very harmful, and can disable the air-
ways natural defence mechanisms against injuries. Hence,
air must be cleaned, warmed and humidified.
There are several mechanisms to protect such a vital func-
tion. Two main complementary mechanisms act to main-
tain the airways as free as possible of foreign bodies and
the airway epithelium from damage due to inhaled path-
ogens and respiratory insults: namely the mucociliary
clearance and the cough clearance. The former constitutes
the first line of defence and the latter is the backup or rein-
forcement if the first one is unable to carry out the task.
Mucus is a unique materia lining all the major body cavi-
ties, produced by the same type of cells: the goblet cells
and the mucous cells of the submucosal glands. In the
lungs, other types of cells produce materials that contrib-
ute to the unique physical properties of mucus, like the
Clara cell, and the type II pneumocyte, which produce the
surfactant factor [1,2]. Mucus can be considered a viscoe-
lastic fluid, since it exhibits both liquid-like (viscous) and
solid-like (elastic) properties [3]. The relative proportions
of elasticity and viscosity are as important in describing
how a material such as mucus behaves when it is sub-
jected to external forces, as are the absolute values of
either parameter by itself.
The mucus lining the airways is a mobile layer constantly
cleared by intimate interaction with cilia. It is also possi-
ble that interaction of mucus with the low velocity airflow
during normal breathing might play a role in mucus clear-
ability. This concept has not been well studied yet. Any
change occurring in one component of the mucus-cilia
unit might lead to disruption of normal mucociliary clear-
ance processes, reducing lung defences and allowing res-
piratory secretions to accumulate and impair pulmonary
function [4].
We are using an integrated approach to gain more insight
into what might occur when the airway mucus-cilia unit is
exposed to novel agents that selectively raise elasticity rel-
ative to viscosity of one of the components: the mucus
macromolecule. This is the reason why we are also review-
ing some theoretical aspects of these components.
The mucus macromolecule (mucin) has a basic, common
and complex biochemical structure. Mucin macromole-
cules consist of oligosaccharide units attached to a proteic
core [5,6]. The physical characteristics of mucus depend
principally on the type and amount of glycoproteins. Vis-
cosity and elasticity are the physical characteristics consid-
ered essential for mucus to function [7], although
adhesivity and spinnability are particularly important in
describing the cough clearability of airway mucus [8].
The frequency of mechanical response is important for
mucus clearance, particularly in the airways. There is an
optimum range among the physical properties that give
mucus its capacity to behave in a balanced manner even
at very different frequencies or rates of displacements.
Low frequency or low amplitude is related to bicellular
clearance, while high frequency/high amplitude is more
closely related to cough clearance [8].
It should be noted that the viscoelasticity relevant to
cough clearance is not necessarily the same as the viscoe-
lasticity relevant to mucociliary clearance. Mucociliary
clearance is defined by low frequency, low amplitude con-
ditions, while cough clearance is governed by high fre-
quency, high amplitude conditions. While there is
generally an association between the low and high fre-
quency/amplitude forms of viscoelasticity, it is possible to
dissociate these parameters to some degree.
Respiratory infection alters mucus, which becomes thick-
ened with the byproducts of the infection and requires
appropriate treatment and possibly physiotherapy and
agents that disrupt the intermolecular interactions of the
airway mucus. This approach has clearly improved the
survival rate of infected patients. Yet altering the physical
properties of mucus while not respecting the effects on
mucus barrier function and aerosolizability of expecto-
rated secretions could lead to problems for both the
patient and the surrounding community.
We implemented this study to test the effects that a spe-
cialized new generation of compounds might have on the
clearance of mucus by ciliary action. This innovative ther-
apy aims to modulate the mucin gel viscoelasticity by
increasing the concentration of crosslinking sites in the
mucin glycoprotein gel network, and/or forming poorly
soluble mucin complexes towards what might be
described as making the mucus "thicker" (a Respiratory
Medicine heresy?), more cohesive, more resistant to
breakup during high speed airflow interaction.
In this study we are starting to build the evidence that the
proposed agents have no adverse effect on the first line of
respiratory defence, namely clearance of mucus by ciliary
action hence assess a previously established fundamentalBMC Pulmonary Medicine 2007, 7:11 http://www.biomedcentral.com/1471-2466/7/11
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criterion: Can we modulate the physical characteristics of
the respiratory secretions to reduce aerosolization without
affecting normal mucociliary clearance function, or even
better improving it? [9].
Methods
To assess the effect of the mucomodulators on the cleara-
bility of airway mucus by ciliary action on a ciliated epi-
thelium and on the intact airways we moved from basic
laboratory to our ex-vivo frog palate exposure model then
to an in-vivo large mammal model. When working with
large mammals we also assessed the effect of the muco-
modulators on the cardio-respiratory pattern, tracheal
mucus clearance, airway patency and mucus viscoelastic
changes. In this study we report the results on mucus
clearance by ciliary action after exposure to mucomodula-
tors.
Exposure models
Frog palate preparation
From a bullfrog, Rana catesbiana, the upper portion of the
head was removed following the procedures described in
previous work [10,11], by cutting with scissors through
from the junction of the posterior pharynx and esophagus
out to the skin of the back and double pithing. This pro-
cedure was carried out after lowering the body tempera-
ture of the frog for 30 – 60 minutes inside a refrigerator to
abolish pain sensations. The palate was examined for
macroscopic lesions, such as ulcers, petechia or redness as
evidence of inflammation. Only palates free of inflamma-
tory indicators were included in this study. Any blood
remaining in the epithelial surface was carefully washed
away, then the excised head was placed palate side facing
upwards on a piece of gauze saturated with frog Ringer
solution (FRS) in a Petri dish.
The palate was placed inside the frog chamber, a wooden
box with a glass top and fitted glass front, and manipu-
lated through glove openings. The humidity inside the
box was maintained near 100% using a Pari jet nebulizer,
and the temperature was kept between 22° and 24°C by
a rheostat-controlled, externally mounted light source.
Before carrying out any measurement, the palate was
allowed to stabilize inside the box for 15 minutes.
The FRS was prepared by mixing standard Ringer injection
with sterile water (2:1). The composition of standard frog
Ringer (in mmol/l) is 90 NaCl, 3 KCl, 2 CaCl2, and 15
NaHCO3 (220 mosm/l). The experimental procedures
involving animals were approved by the Health Sciences
Animal Policy and Welfare Committee, University of
Alberta
Mucus transport velocity (MTV) determination in the frog palate
The palate was placed under a dissecting stereomicro-
scope provided with a reticulated eyepiece. Mucociliary
clearance was determined by observing the movement of
particles of charcoal powder gently deposited on a sample
of frog mucus on the palate surface; its clearance was vis-
ually monitored and MTV determined. The displacement
of 3 – 5 μL of endogenous frog mucus sample was calcu-
lated by dividing the distance traveled by the transit time
across the 0.3 in (7.62 mm) segment marked between 0.1
and 0.4 inches in the graduated eyepiece. To determine
the mucus transport velocities of the control and of the
exposed, at least five measurements of the time required
for the mucus sample to travel the defined distance were
made.
Mammalian exposure model
Random source, mixed-breed dogs of either sex, free of
respiratory tract infections or other observable respiratory
tract pathology, weighing from 15 to 20 kg, were
employed in this study. Fasting experimental animals
were pre-medicated with xylazine (2 mg/kg i.1 m.), and
then a vein in either anterior leg was catheterized. After
observing a good flow rate of the solution administered
intravenously, the dog was anesthetized with the lowest
dose of sodium pentobarbital (15 – 20 mg/kg i.v. slowly
administered) required to allow the animal to breathe
spontaneously and to suppress ocular reflexes. Supple-
mental doses of sodium pentobarbital in bolus were
administered as needed during the experiment.
The dogs were placed in supine position, immediately
intubated as shallowly as possible with a # 8 to 9 endotra-
cheal tube, and covered to minimize the fall in core tem-
perature. Several manoeuvres were implemented to make
sure that the ETT was inside the trachea, and only then was
its balloon inflated and the tube fixed with tape to the
upper jaw and to the fangs to avoid displacement.
Vital signs
heart rate, breaths per minute, temperature, and respira-
tory-cardiac pattern were constantly monitored through-
out the experiment. During the experiment each animal
inhaled either nebulized normal saline solution (sham
exposure) or nebulized mucomodulators diluted in nor-
mal saline solution (0.9% NaCl) in three different con-
centrations. They were slightly hyperosmolar compared to
normal saline solution, except for the highest dose of XL
"B" (sodium tetraborate, 0.1 M), which reached an esti-
mated osmolarity of 0.6 Osm, the equivalent of ca. 1.8%
NaCl. XL "D" (high molecular weight dextran), based on
a macromolecule, increases osmolarity very minimally.
After the experiment the animals were euthanized with an
overdose of sodium pentobarbital plus potassium chlo-BMC Pulmonary Medicine 2007, 7:11 http://www.biomedcentral.com/1471-2466/7/11
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ride intravenously and the trachea was excised for his-
topathological studies.
In-vivo tracheal mucus velocity (TMV) in dogs
Direct evaluation of mucus clearability was determined by
a bronchoscopic technique. A drop (10 μl) of a suspen-
sion of powdered charcoal in saline solution was gently
deposited onto the right side of the lower tracheal wall,
approximately 1 cm above the carina. The position of the
moving leading edge of the charcoal spot was located by
advancing the tip of the bronchoscope to lay above the
spot.
The exterior end part of the endotracheal tube allowed us
to mark that position in the bronchoscope as the initial
point. Setting the chronometer for five minutes, we
started retracting the bronchoscope as the leading edge of
the charcoal spot approached the upper part of the tra-
chea, then marking on the bronchoscope the final point
where the spot reached the internal tip of the ETT, or at the
end of the five minutes period, and then measuring the
distance between those two points. Transit times were five
minutes or less depending on the rapidity with which the
charcoal front approached the inlet of the endotracheal
tube. TMV was computed as the distance in millimeters
traveled divided by the time elapsed in minutes.
TMV measurements were made: a) once immediately after
initial intubation of the trachea, prior to any drug inter-
vention (baseline), b) twice after 30 minutes aerosoliza-
tion of saline solution (control), and c) twice after 20
minutes of each dose of the experimental drug delivered
by aerosol (six measurements). Three aerosol concentra-
tions were delivered: Low = 0.001 M; Med = 0.01 M; High
= 0.1 M. We made a total of nine mucociliary clearance
measurements per animal per experiment.
The first sample of mucus (baseline) was obtained using
the brush technique and no removal of the ETT was
required. Then the ETT was removed immediately after
every TMV measurement to allow for mucus collection,
and rapidly a second endotracheal tube was introduced
and fixed after both doses of saline and after both doses of
the low, medium and high concentration delivery of test
drugs. Every dog had the ETT removed and reinserted
eight times during the experiment. After every tracheal
intubation the animal was allowed to rest during five min-
utes while normal saline solution was delivered by aero-
sol.
Mucus collection
Brush technique
The brush technique was used only once at the beginning
of the experiment for baseline determination. Mucus was
collected using the bronchoscopic technique developed
by Jeanneret-Grosjean et al [12] from the same tracheal
level but in the opposite side from where charcoal was
deposited for TMV measurement. A cytology brush was
gently placed in direct contact with the tracheal mucosa
for five minutes, thus allowing for the collection of several
microliters of mucus. The mucus sample was scraped from
the brush and immediately covered with light paraffin oil
and stored in a freezer at -30°C.
Endotracheal tube technique
Airway mucus was collected: a) twice after aerosolization
of saline solution (as control), and b) twice after aerosoli-
zation of the experimental drug in low (0.001 M),
medium (0.01 M) and high (0.1 M) concentrations (six
collections) using the endotracheal tube (ETT) technique
[13] for a total of eight ETT mucus sample collections per
animal.
Immediately after every aerosolization and TMV measure-
ment, the dog was extubated to collect mucus adhering to
the tube. Another clean endotracheal tube was immedi-
ately placed in the trachea. The mucus coating the tube
was covered with light paraffin oil (No. 0-121; Fisher Sci-
entific, Fair Lawn, NJ), to prevent dehydration and
removed by scraping the ETT with the edge of a forceps,
placed into a 15 ml plastic test tube containing about 8 ml
of light paraffin oil and stored in a deep freezer under -
30°C. This method optimizes the quantity of mucus col-
lected, which is important for the development of further
biochemical assays.
Mucomodulator exposures
Frog palate exposure
We prepared several dilutions of the mucomodulators
employed (from 10-1 M to 10-8 M). We determined the
baseline MTV after 15 min of stabilization of the palate
inside the frog box, previous to any intervention. We
exposed the palate by gently depositing 5 μl of the dilu-
tion of the agent to test on the proximal portion of the pal-
ate, proceeding from the lowest concentration to the next
high concentration.
After baseline determination, we followed a pattern of 20
minutes period of rest under 100% humidity and room
temperature inside the frog box. Then timing every run to
measure MTV five times after applying through an Eppen-
dorf micropipette a) 5 μl of frog Ringer (control), b) 5 μl
of XL 10-8 M, c) 5 μl of XL 10-7 M, let the palate rest for 20
minutes, then MTV measure again after d) 5 μl of frog
Ringer, e) 5 μl of XL 10-6 M, f) 5 μl of XL 10-5, let the palate
rest for 20 minutes, and so on until concentration 10-1 M.
At the end of the experiment we have performed one MTV
baseline measurement, three MTV after FR (control) and
eight MTV after every different concentration of XL.BMC Pulmonary Medicine 2007, 7:11 http://www.biomedcentral.com/1471-2466/7/11
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In-vivo dog exposure
We exposed spontaneously breathing, lightly anesthetized
dogs to three different concentrations of both mucomod-
ulators XL "B" and XL "D" (10-3 M, 10-2 M and 10-1 M) and
to normal saline solution XL "S" as sham exposure. Drugs
were delivered by aerosol through an endotracheal tube
using a Pari LC Star jet nebulizer system set at 8 l/min
measured by a Puritan flow meter. We nebulized 5 – 7 ml
of each concentration of both mucomodulator XL"B" and
XL"D" for about 20 minutes (~0.35 ml/min) for a dose of
approximately 0.1 mg/kg, 1 mg/kg and 10 mg/kg per
mucomodulator.
Baseline TMV
We measured the tracheal mucus velocity baseline, as
explained above, before any intervention was performed.
This was followed by collection of a mucus sample using
the brush technique.
Control measurements
Normal saline solution was delivered by aerosol during
30 minutes, and then we measured TMV (a) for five min-
utes. After the clearance of mucus was measured the
endotracheal tube was removed for mucus collection (i).
Another endotracheal tube was immediately inserted
inside the trachea and fixed, and saline solution was aero-
solized for five more minutes; after this period the animal
was left to breathe spontaneously for another five min-
utes.
After the period of rest, TMV (b) was measured again for
five minutes; we then removed the ETT for mucus collec-
tion (ii) and another tube was reinserted, followed by a
period of aerosolized saline solution and a period of rest,
both for five minutes.
Mucomodulator exposures
The mucomodulator to test was randomly selected prior
to initiating the experiment. A solution in low concentra-
tion (0.001 M) of the selected mucomodulator (XL "S",
XL "B" or XL "D") was delivered by aerosol during 20 min-
utes, and then we measured TMV (c) for five minutes.
After the clearance of mucus was measured the endotra-
cheal tube was removed for mucus collection (iii).
Another endotracheal tube was immediately inserted
inside the trachea and fixed, and saline solution was aero-
solized for five more minutes, after this period the animal
was left to breathe spontaneously without any interven-
tion for another five minutes.
Immediately after the rest period, TMV (d) was measured
again for five minutes, and then the ETT was removed for
mucus collection (iv) and another tube was inserted and
fixed, followed by periods of aerosol of saline solution
and of rest, both for five minutes.
The same procedure described above for XL low concen-
tration was used for delivering the subsequent XL medium
(0.01 M) and XL high (0.1 M) concentration solutions of
the selected mucomodulator.
Tracheal tissue samples
Following the second TMV measurement after the admin-
istration of the high dose of XL and removal of the ETT, an
overdose of a cocktail of sodium pentobarbital plus potas-
sium chloride was administered intravenously in bolus to
the animal. Through an open chest incision the trachea
and both mainstem bronchi were excised, and immersed
in formalin 20% for immunology and histopathology
studies.
Mucomodulator agents
We have six different approaches that have the potential
to accomplish these goals that we intend to test and
develop [9]. However, in this study we report the effect of
two of them, XL "B" and XL "D" as well as XL "S" (normal
saline solution) the sham exposure, on the frog palate and
on the respiratory airway of lightly anesthetized dogs.
One approach we tried was the use of sodium tetraborate
solutions (mucomodulator "B", XL "B"), which cause
reversible crosslink formation between galactose units
that are the major neutral sugar component of mucins. In
model studies using vegetable polysaccharides, sodium
tetraborate preferentially raises elasticity relative to viscos-
ity, and would favor mucociliary clearability at the
expense of cough clearability and aerosolizability [3]. We
have recently reported studies on the effect of added
borate on the clearability and aerosolizability of mucus
simulants. The results were quite striking: we were able to
achieve increased "expectoration" in our cough machine
model, along with normal mucociliary clearance in the
frog palate model, and yet achieve our desired target of a
significant reduction in fine aerosol formation [9].
A second approach was to administer high molecular
weight dextran (mucomodulator "D", XL "D). HMW dex-
tran has approximately the same molecular weight as the
subunits of mucin macromolecules; in this case mucin-
dextran crosslinks are approximately as effective as the
original mucin-mucin crosslinks. Interestingly, HMW dex-
tran tends to raise elasticity relative to viscosity (as indi-
cated by the increase in spinnability); thus its use would
tend to inhibit aerosolizability, which will depend on
spinnability [14] while maintaining mucociliary clearabil-
ity.
Dextran is a natural product used in the food, biochemical
and pharmaceutical industries for more than five decades.
In vitro synthesis of microbial dextrans is obtained from
the action of dextransucrase from Leuconostoc mesenter-BMC Pulmonary Medicine 2007, 7:11 http://www.biomedcentral.com/1471-2466/7/11
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oides on a sucrose substrate. Dextran molecular weight
and the degree of branching can be influenced during syn-
thesis by variables like substrate concentration and tem-
perature.
Statistical analysis
Data are expressed as mean ± standard deviation unless
otherwise stated. A paired Student-T test was used for sim-
ple comparison. Newman-Keuls analysis was applied for
repeated measurements. The Bonferroni correction was
also used for statistical adjustment. The level of signifi-
cance was set at 5%.
Results
All frog palates used in these experiments appeared mac-
roscopically healthy, and after the stabilization period
inside the frog box, all showed normal ciliary clearance
function.
Epithelial exposure
The frog palate exposed to XL "B" had a baseline measure-
ment of mucus cleared by cilia of 0.36 mm/sec and
showed an average of MTV control measurements of 0.36
mm/sec. Applying the lowest concentration of the muco-
modulator XL "B" (10-8 M), immediately after the deter-
mination of the duplicate control measurement, it
showed an average of 0.43 mm/sec in both sets of runs.
Following with the next concentration (10-7  M) we
obtained an average of 0.45 mm/sec in both sets of runs.
After testing all the four control measurements and the
eight different concentrations we obtained a grand aver-
age of 0.37 mm/sec for the controls and 0.36 in mucus
clearance velocity for all the XL "B" exposure. Comparison
of both groups, control and experimental, using the t-test
showed no statistical difference. However we noticed a
decreasing trend in the transport rate as time elapsed (Fig-
ure 1).
The frog palate exposed to XL "D" had a baseline measure-
ment of mucus cleared by cilia of 0.35 mm/sec and
showed an average of MTV control measurements of 0.36
mm/sec. Applying the lowest concentration of the muco-
modulator XL "D" (10-8 M), immediately after the deter-
mination of the duplicate control measurement, it
showed an average of 0.43 mm/sec. Following with the
Effect on mucus transport velocity of the frog palate after topical application of eight different molar concentration of muco- modulators "B" and "D" Figure 1
Effect on mucus transport velocity of the frog palate after topical application of eight different molar concentration of muco-
modulators "B" and "D". Duplicate (five runs) measurement per control (four) and per dose (eight) plus one baseline measure-
ment. (Total runs per experiment: 65). Control Grand Mean: 36 mm/min.
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next concentration (10-7 M) we obtained an average of
0.39 mm/sec in both sets of runs.
After testing all the four control measurements and the
eight different concentrations we obtained a grand aver-
age of 0.36 mm/min for the control and 0.35 mm/sec in
mucus velocity clearance for the XL "D" exposure. Com-
parison of both groups, control and experimental, using
the t-test showed no statistical difference.
Mammalian exposure
A total of seven male and six female dogs, 16 kg weight
average, were exposed to mucomodulators: six of them to
XL "D" (4 M – 2 F), five to XL "B" (2 M – 3 F) and two to
Effect of three different doses of mucomodulator XL "B" (sodium tetraborate, five dogs), XL"D" (high molecular weight dex- tran, six dogs) and XL "S" (normal saline solution, sham exposure, two dogs) on normalized tracheal mucus velocity in sponta- neously breathing anesthetized dogs Figure 2
Effect of three different doses of mucomodulator XL "B" (sodium tetraborate, five dogs), XL"D" (high molecular weight dex-
tran, six dogs) and XL "S" (normal saline solution, sham exposure, two dogs) on normalized tracheal mucus velocity in sponta-
neously breathing anesthetized dogs. **Newman-Keuls: p < 0.01 with respect to control. ! Bonferroni: p < 0.05 (correlated 
groups). † Dunnett: p < 0.01 (treatments versus control).
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Table 1: Percentage of Change of TMV Compared with Baseline
XL "S" XL "D" XL "B"
Baseline 100 100 100 100 100 100 100 100 100
Slow -32 -30 +9 +60 +109* +66∞ +30 +65 +28*
Non-Slow +24 +34 +9 +18 +4 +20 +6 +35§ +24
* = p < 0.05, compared with Baseline
§ = p < 0.01, compared L vs. M doses XL "D", ∞ = p < 0.06, compared with medium dose XL "D"BMC Pulmonary Medicine 2007, 7:11 http://www.biomedcentral.com/1471-2466/7/11
Page 8 of 13
(page number not for citation purposes)
XL "S"(1 M – 1 F). The skin temperature of the dogs
remained stable around 34°C throughout the experimen-
tal time. The respiratory and cardiac frequency as well as
the respiratory pattern remained with normal rhythm also
stable at rate (12 breaths/min, 60 beats/min), except
when the animal was restless when awakening and
required more anesthetic.
All of the animals involved had at the start of the experi-
ment a normal healthy looking airway mucosa, with no
hypersecretion, no ulcers and no visible inflammation. Of
all experimental animals used, five dogs yielded either a
very small sample of mucus (4) or no sample at all (1)
when using the baseline brush technique collection. One
dog that yielded a very small sample using the brush tech-
nique consistently yielded either a small sample or no
sample at all throughout the experiment while collecting
mucus using the ETT mucus collection technique.
During the mucus collection using the ETT technique it
was observed that in dogs that received either XL "D" or
XL "B", even when using the lowest concentration, but not
in those sham exposed (XL "S"), the mucus samples were
mostly collected from inside the tube and very little from
the outside portion of the tube. It was also observed that
the samples of mucus collected from the inside or outside
portion of the ETT in dogs that inhaled mucomodulators
slid off the tube very easily when it was placed in a vertical
position. The latter was not observed in those dogs sham
exposed.
Every dog had its own initial control of tracheal mucocil-
iary linear velocity measured at the beginning of the
experiment (baseline). We express the normalized percent
of change in TMV after exposure to mucomodulators
compared to that initial control (NTMV%). In general, the
NTMV% data indicate a sustained 40% mean increase in
tracheal mucociliary clearance rate in the mucomodulator
Effect of normal saline solution on tracheal mucus velocity in two spontaneously breathing anesthetized control dogs Figure 3
Effect of normal saline solution on tracheal mucus velocity in two spontaneously breathing anesthetized control dogs. Two 
measurements per dose.
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treated dogs after using the three different doses of both
experimental compounds, compared to up to 7% increase
in sham exposed dogs (Figure 2).
For NTMV% in sham exposed dogs versus those exposed to
XL "B" and to XL "D", the Newman-Keuls test showed that
there was a significant statistical difference when compar-
ing control vs. XL "B" medium and high dose, as well as
between low vs. medium dose at the p < 0.01 level (Figure
2). The Bonferroni correction indicated a significant dif-
ference only when comparing control vs. XL "B" high dose
at the p < 0.05 level. The Dunnett's procedure (treatment
versus control) also indicated a statistical significant dif-
ference only with the XL "B" medium dose at the p < 0.01
level.
However, while performing the control measurement of
tracheal mucus clearance we observed that a group of five
dogs (40%), of either sex, presented an average control
TMV of 2.0 mm/min (2 with XL "D", 2 with XL "B" and 1
with XL "S") compared to an average control rate of 4.6
mm/min in the eight (8) remaining experimental ani-
mals.
Within each experimental drug group, we grouped ani-
mals in two separate subgroups: those with slow and non-
slow TMV based on the initial tracheal clearance rate (Fig-
ures 3, 4 and 5). Then we carried out a further t-test anal-
ysis of NTMV% comparing control versus dose used as well
as between doses within the slow and non-slow subgroups
in each of the three exposed groups: sham, "D" and "B"
(Table 1).
Discussion
The focus of this study is on the physiological function of
the mucociliary clearance apparatus with and without
exposure to mucomodulators in both the ex-vivo epithelial
model and the in-vivo large mammal model.
Comparison of the effect of different concentrations of sodium tetraborate (XL "B") on dogs with slow versus non-slow tracheal  mucus velocity Figure 4
Comparison of the effect of different concentrations of sodium tetraborate (XL "B") on dogs with slow versus non-slow tracheal 
mucus velocity. The effect is larger in the slow group.
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Major findings in this study include: a) The two epithelial
models used in this study, the ex-vivo frog palate and the
in-vivo mammalian model, appear to be appropriate and
complement each other to study the effects that our
mucomodulators exert on the mucociliary clearance
defence mechanism; b) the mucin macromolecules of the
herein used in-vivo  mammalian model (dog) showed
selective crosslinking behavior after exposure to muco-
modulators as it was previously shown in mucus simu-
lants: increased elasticity, expressed by increased thread
formation capacity and is more easily clearable from
intact airways; c) the physiological function of the muco-
ciliary apparatus was not negatively affected in either of
the two epithelial models; d) modulated airway mucus is
better cleared from an intact airway system and normally
functioning respiratory system after exposure to muco-
modulators; e) data presented in this study allow us to
assure that we have complied with the fundamental
requirement criteria established in the initial phase of
developing the concept of mucomodulation: Can we
modulate the physical characteristics of the respiratory
secretions to reduce aerosolization without affecting nor-
mal mucociliary clearance function, or even better
improving it? [9].
In this study we combined the use of two very different cil-
iated epithelial models to have a better assessment of the
effect that crosslinking agents have on clearance of mucus
by interaction with cilia. Several observers had raised
questions previously about the adequacy of the frog palate
as a model to assess airway mucus clearance, since in the
first place it belongs to a non-mammalian species, in
addition that it is non-respiratory. However, this ciliated
epithelium has a well developed mucus blanket that
works in coordination with cilia similar to that observed
in other mammals including humans. This epithelial
model also permits us to assess mucus clearance by cilia
interaction only without the airflow factor [15].
Comparison of the effect of different concentrations of high molecular weight dextran (XL "D") on dogs with slow versus non- slow tracheal mucus velocity Figure 5
Comparison of the effect of different concentrations of high molecular weight dextran (XL "D") on dogs with slow versus non-
slow tracheal mucus velocity. The effect is larger in the slow group.
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The in-vivo mammalian model, using anesthetized dogs,
allowed us to assess the effects that our mucomodulators
exert on the mucociliary clearance defence mechanism in
an intact airway system and normally functioning respira-
tory system. The intact airway system in our dog model
permitted us to also assess the potential contribution of
other factors in clearing a modulated mucus, particularly
airflow during normal spontaneous breathing.
Data obtained from the dogs showed that inhalation of
three different doses of mucomodulators did not
adversely affect the cardio-respiratory pattern even after
the different procedures involved and several hours that
lasted every experiment. The data support the observation
that cilia were not functionally affected after exposure to
mucomodulators.
After aerosolizing the mucomodulators and while collect-
ing the samples of mucus, we observed an increase in
thread formation capacity of the mucus even when using
low concentration doses. Since we did not have a
Filancemeter on site, we anchored the mucus in a fang of
the dog and used a wooden pick or a needle to pull the
mucus and observed it stretching and forming long
threads before rupture. With no mucomodulators, the
mucus threads ruptured after stretching up to 5 to 8 mm,
while it ruptured after stretching around 30 to 50 mm fol-
lowing exposure to mucomodulators.
During and after aerosolizing the mucomodulators and
while collecting the samples of mucus, we examined the
airways of the experimental dogs, as far down in the air-
way tree as the bronchoscope allowed access, to visually
assess bronchial patency and possible obstruction of the
airways caused by the modulated mucus. We observed the
airways in all experimental animals free of obstruction
throughout the study period. All dogs, either exposed to
placebo or mucomodulators, maintained a normal respi-
ratory rhythm and frequency throughout the experiment
that might suggest they were free of respiratory distress.
However more studies on this topic are required to arrive
to a more definite conclusion.
After showing in the mammalian model that instead of
deterioration of the mucociliary clearance mechanism
there was a clear improvement in tracheal mucus clear-
ance, we carried out an additional trial to assess the effect
of those mucomodulators on cough and aerosol genera-
tion pattern in the same dog model. After 20 minutes of
nebulization of capsaicin solution, the dog did not cough
or sneeze at all. We aborted the experiment after that time
and after the researchers were constantly coughing. We
still cannot find the reasons why capsaicin did not make
the dog cough. Veterinarians consulted about this event
found no answer either.
The modulated "thicker" mucus neither plugged the air-
ways of the experimental (mammalian) subjects, as far
down in the airways tree as the bronchoscope allowed us
to assess, or was the tracheal mucus clearance rate nega-
tively affected. On the contrary and unexpectedly, tracheal
mucus velocity systematically increased even with the
lowest dose of either mucomodulator administered.
The observations addressed in the previous paragraph
may help to respond to the greatest concern expressed by
some researchers and clinicians when they first learn
about mucomodulators, "that crosslinking the mucus layer
in this way, will make mucus 'thicker' and might obstruct the
airways in exposed subjects". We have started to build the
evidence that the proposed drugs that increase the con-
centration of crosslinking sites in the mucin glycoprotein
gel network do not gum up airway secretions, do not plug
the airways and have no adverse effect on the clearance of
airway mucus in a normally functioning respiratory sys-
tem of a mammalian model. However, the mucomodula-
tors we tested in this study might still have some effects in
areas that were not visible or measurable through the
bronchoscope, such as in smaller airways or alveolar tis-
sue. More studies are required before reaching a definite
conclusion to rule out side-effects of the mucomodulators
on respiratory secretions of smaller airways and alveolar
tissue or on gas exchange.
Since mucus clearance in the airways is a function of the
intimate interaction of the anatomophysiological bicellu-
lar unit, ciliated cells and mucus producing cells, this
study has allowed us to determine that no functional dis-
ruption of the normal clearance of mucus occur when we
selectively alter the elastic property of mucus.
The ex-vivo frog palate model is an excellent model for
assessing the effect of the mucomodulators on the mucus-
cilia interaction undisturbed by internal or external fac-
tors like airflow. The in-vivo  mammalian model is an
excellent model for assessing in an integral manner the
effect of the mucomodulators on the mucus interacting
with cilia as well as with several other respiratory compo-
nents like airflow during normal breathing.
Selective modulation of the elastic properties of mucus in
our mammalian model indicates that the modified mac-
romolecule of mucin is engineered to work in an exquisite
manner with the low speed airflow during normal breath-
ing in a normally functioning respiratory system.
Several years ago we had the opportunity to analyze a
sample of tracheobronchial mucus of a patient diagnosed
with primary ciliary dyskinesia and the mucus showed to
have predominantly more elastic properties. Individuals
with this genetic syndrome depend completely on airflowBMC Pulmonary Medicine 2007, 7:11 http://www.biomedcentral.com/1471-2466/7/11
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interaction for airway mucus clearance since they have a
totally dysfunctional cilia apparatus, i.e. immotile cilia.
This finding guided us in our approach to develop the
mucomodulators.
An additional mechanism to explain the enhanced mucus
clearance observed in our mammalian model could be
that inhaled mucomodulators stimulate cells producing
surfactant factor. The possible presence of a surfactant fac-
tor both within and between the sol and gel phase of the
mucus may play a role in facilitating mucus clearability or
cough clearability, by allowing the mucus layer to slide
easily and more effectively on top of the cilia. This may
explain the observation of mucus sliding in an easier man-
ner from the endotracheal tube surface.
There may occur a combination of these hypotheses, as
well as other possible new mechanisms, such as the
increased osmolarity composition of the aerosolized solu-
tions enhancing airway secretions hydration. However,
given the fact that tracheal mucus velocity peaked with the
intermediate dose of XL "B" (equivalent of 1.0% NaCl),
and not with the highest dose (equivalent of 1.8% NaCl),
the contribution of hyperosmolarity is not likely the
major explanation for the stimulation of TMV. We antici-
pate that further work is needed to clearly define the
mechanisms involved in the enhanced clearance of airway
secretions when exposed to our mucomodulators.
Both mucomodulators used in this study exhibited an
effect in modulating the mucus macromolecule of the air-
ways of the dogs by increasing elasticity. We may rightly
assume from the latter that poorly soluble mucin complex
or more cohesive mucus have been formed that will be
more resistant to break up during high speed airflow inter-
action, hence expelling less particles as aerosol.
For centuries people around the world from different non-
related cultures have been extensively searching plants,
minerals and animal products to best improve functions
and defence mechanisms for pulmonary disorders involv-
ing abnormal mucus and hypersecretion. In this study we
have successfully used a natural product: high molecular
weight dextran, a bacterial biopolymer produced by the
Leuconostoc mesenteroides that showed promising proper-
ties to enhance airway hygiene and airborne infectious
diseases.
Results from this study indicate that the critical measures
of success, namely to maintain airway clearance has been
proved in both ex-vivo as well as in-vivo epithelial models.
The degree of improvement in tracheal mucociliary clear-
ance using our mucomodulators is far better than that
achieved by using current approaches in the same animal
model. Our mucomodulators can be considered as an
enhanced new generation of compounds able to improve
airway hygiene and respiratory host defence.
Data in this study complement with our data previously
published to support the concept that our mucomodula-
tors can achieve a dual goal of reducing aerosolization
without impairing lung clearance, since the two most
important clearance mechanisms of the respiratory sys-
tem remain functional. Mucomodulators have no
reported antitussive action hence no cough mechanism is
affected.
Conclusion
We have acquired preliminary evidence that mucomodu-
lators that increase cohesive interactions between mucin
macromolecules make mucus more easily clearable, most
likely by airflow-dependent mechanisms. Increasing the
cohesiveness in this manner might help to reduce fine aer-
osol formation during coughing or sneezing – a desirable
advantage in helping to control the spread of airborne
infections.
Mammalian subjects in this study showed a very different
tracheal mucus velocity from other studies using a similar
model. We do not have an explanation for this matter.
Both mucomodulators enhanced tracheal mucus velocity
in all those exposed. However, tracheal mucus velocity
was best enhanced in those with slower mucus clearance.
This finding might be of particular use for those individu-
als who have impaired mucociliary clearance.
We anticipate other potential benefits that relate to
enhancing mucus clearance, a major consideration in con-
ditions of impaired airway secretion management i.e.
patients suffering from COPD, spinal cord injury, neu-
romuscular disease or those in intensive care units and/or
those who require assisted mechanical ventilation.
These findings might assist us in enhancing the knowl-
edge of the changes in the mucociliary apparatus that
occur after exposure to mucomodulator products, with
the goal to understand how these changes relate to an
improved and innovative management of chronic airway
pathologies in humans.
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